Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma

J W van Sandick, J J van Lanschot, B W Kuiken, G N Tytgat, G J Offerhaus, H Obertop, J W van Sandick, J J van Lanschot, B W Kuiken, G N Tytgat, G J Offerhaus, H Obertop

Abstract

Background: The efficacy of endoscopic biopsy surveillance of Barrett's oesophagus in reducing mortality from oesophageal cancer has not been confirmed.

Aims: To investigate the impact of endoscopic biopsy surveillance on pathological stage and clinical outcome of Barrett's carcinoma.

Methods: A clinicopathological comparison was made between patients who initially presented with oesophageal adenocarcinoma (n = 54), and those in whom the cancer had been detected during surveillance of Barrett's oesophagus (n = 16).

Results: The surveyed patients were known to have Barrett's oesophagus for a median period of 42 months (range 6-144 months). Prior to the detection of adenocarcinoma or high grade dysplasia, 13 to 16 patients (81%) were previously found to have low grade dysplasia. Surgical pathology showed that surveyed patients had significantly earlier stages than non-surveyed patients (p = 0.0001). Only one surveyed patient (6%) versus 34 non-surveyed patients (63%) had nodal involvement (p = 0.0001). Two year survival was 85.9% for surveyed patients and 43.3% for non-surveyed patients (p = 0.0029).

Conclusions: The temporal course of histological progression in our surveyed patients supports the theory that adenocarcinoma in Barrett's oesophagus develops through stages of increasing severity of dysplasia. Endoscopic biopsy surveillance of Barrett's oesophagus permits detection of malignancy at an early and curable stage, thereby potentially reducing mortality from oesophageal adenocarcinoma.

Figures

Figure 1
Figure 1
Duration and frequency of endoscopic surveillance with the accompanying histological findings in 16 patients undergoing surveillance of Barrett's oesophagus. Black dots represent endoscopic examinations at which no biopsy specimens were obtained.
Figure 2
Figure 2
Distribution of pathological stage.
Figure 3
Figure 3
Postoperative survival. The numbers in the box refer to the number of patients at risk at 12 month intervals.

References

    1. JAMA. 1991 Mar 13;265(10):1287-9
    1. Gastroenterol Clin Biol. 1995 May;19(5):475-81
    1. Gut. 1991 Dec;32(12):1441-6
    1. Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9
    1. Hum Pathol. 1992 May;23(5):479-82
    1. Ann Surg. 1992 Jul;216(1):35-43
    1. Ann Thorac Surg. 1992 Aug;54(2):199-204
    1. Gut. 1992 Sep;33(9):1155-8
    1. Gut. 1992 Nov;33(11):1454-8
    1. Gastroenterology. 1993 Feb;104(2):510-3
    1. J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8
    1. Surg Oncol. 1995 Jun;4(3):163-71
    1. Ann Surg. 1996 May;223(5):585-9; discussion 589-91
    1. Ann Surg. 1996 Jul;224(1):66-71
    1. Gut. 1996 Jul;39(1):5-8
    1. Gut. 1996 Oct;39(4):574-9
    1. J Natl Cancer Inst. 1968 Sep;41(3):665-81
    1. N Engl J Med. 1976 Aug 26;295(9):476-80
    1. J Natl Cancer Inst. 1980 May;64(5):1263-72
    1. Hum Pathol. 1983 Nov;14(11):931-68
    1. Gastroenterology. 1984 Oct;87(4):927-33
    1. N Engl J Med. 1985 Oct 3;313(14):857-9
    1. N Engl J Med. 1986 Aug 7;315(6):362-71
    1. Gastroenterology. 1987 Jan;92(1):118-24
    1. Ann Intern Med. 1987 Oct;107(4):592-3
    1. Gastroenterology. 1988 Jan;94(1):81-90
    1. Gastroenterology. 1989 May;96(5 Pt 1):1249-56
    1. Endoscopy. 1989 Jul;21(4):177-85
    1. Gastroenterology. 1990 Oct;99(4):918-22
    1. Ann Surg. 1990 Oct;212(4):528-40; discussion 540-2
    1. Am J Surg. 1991 Jan;161(1):97-9; discussion 99-100
    1. Ann Surg. 1991 Feb;213(2):122-5
    1. Gastroenterology. 1993 Jul;105(1):40-50
    1. Am J Gastroenterol. 1993 Nov;88(11):1832-6
    1. J Thorac Cardiovasc Surg. 1994 Apr;107(4):1059-65; discussion 1065-6
    1. Am J Gastroenterol. 1994 Aug;89(8 Suppl):S160-8
    1. Cancer. 1994 Aug 15;74(4):1225-9
    1. Hum Pathol. 1994 Oct;25(10):982-93
    1. J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2
    1. Arch Intern Med. 1991 Nov;151(11):2212-6

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren